Overview

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845 can be established following single oral doses.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Spironolactone